Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | CCR7 | P32248 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30716876 | 1.00 | ADORA3 (0.39) | ADORA3CCR7SMN1; SMN2PTPN11ADORA2A | |
| SCHEMBL4065245 | 0.99 | ADORA3 (0.40) | ADORA3CCR7SMN1; SMN2PTPN11ADORA2A | |
| SCHEMBL17595255 | 0.75 | MAP3K5 (0.35) | SMN1; SMN2PTPN11CDK2CCNB2CDK1 | |
| SCHEMBL3245634 | 0.75 | PDE8B (0.36) | CDK2CCNB2CDK1CCNB1CCNA2 | |
| SCHEMBL258582 | 0.73 | MAP3K5 (0.37) | MAP3K5 | |
| SCHEMBL17800815 | 0.73 | PDE8B (0.35) | CDK2CCNB2CDK1CCNB1CCNA2 | |
| SCHEMBL16146486 | 0.72 | PAK1 (0.49) | ADORA3ADORA2AADORA1PAK1 | |
| SCHEMBL2946030 | 0.71 | PAK1 (0.31) | PTPN11PAK1 | |
| SCHEMBL16145849 | 0.71 | PAK1 (0.47) | ADORA3ADORA2AADORA1PAK1 | |
| SCHEMBL756296 | 0.70 | HASPIN (0.33) | SMN1; SMN2CDK2CDK1CCNB1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | ASTROCYTE PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4329773-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | Astrocyte Pharmaceuticals, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117241803-A | Purine nucleosides, intermediates and methods of making the same | 阿斯特罗赛特制药公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2022232810-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2009034386-A1 | DERIVATIVES OF ADENINE AND 8-AZA-ADENINE AND USES THEREOF-796 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009034386-A1 | DERIVATIVES OF ADENINE AND 8-AZA-ADENINE AND USES THEREOF-796 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | NUDT1, PNP, UMPS | ADORA3 42/4885CCR7 884/4885SMN1; SMN2 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.